A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ASO / antisense oligonucleotide

[Related PubMed/MEDLINE]
Total Number of Papers: 789
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ASO  (>> Co-occurring Abbreviation)
Long Form:   antisense oligonucleotide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A combinatorial approach increases SMN level in SMA model mice. SMA, SMN
2022 A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer. BLBC, KLF5, lncRNAs
2022 A pathogenic proteolysis-resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function. HD, mHTT, WT
2022 Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. ADME, ADRs, FDA
2022 Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma. IGF1R, NPs, TK
2022 Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. ADRs, FDA
2022 Altered Biodistribution and Hepatic Safety Profile of a Gapmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids. GuNA, KD
2022 Analysis of therapeutic nucleic acids by capillary electrophoresis. CE, CRISPR, mRNA, siRNA
2022 Angiopoietin-like 3: An important protein in regulating lipoprotein levels. ---
10  2022 Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease. mRNA, shRNA, siRNA
11  2022 Antisense Oligonucleotide-Based Therapy on miR-181a-5p Alleviates Cartilage Degradation of Temporomandibular Joint Osteoarthritis via Promoting SIRT1. TMJOA, UAC
12  2022 Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice. APOL1
13  2022 Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1. DM1
14  2022 Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation. HF, PLN
15  2022 Apolipoprotein CIII Reduction Protects White Adipose Tissues against Obesity-Induced Inflammation and Insulin Resistance in Mice. apoCIII, HFD, SAT, WAT
16  2022 Brain somatic mutations as RNA therapeutic targets in neurological disorders. siRNA
17  2022 Chimeric Peptide-Based Biomolecular Constructs for Versatile Nucleic Acid Biosensing. PNA, QCM, SBP, SBP-ASO, SBP-PNA, SPR
18  2022 Cholesterol-Mediated Seeding of Protein Corona on DNA Nanostructures for Targeted Delivery of Oligonucleotide Therapeutics to Treat Liver Fibrosis. ---
19  2022 Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks. CMAP, MUNE, NMJ, PND, SMA
20  2022 Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. SMA
21  2022 Current and Possible Future Therapeutic Options for Huntington's Disease. Cas, CRISPR, HD, HTT, mHTT, RNAi, TALEN, ZFP
22  2022 DDX5 mRNA-targeting Antisense Oligonucleotide as a new promising therapeutic in combating Castration-Resistant Prostate Cancer. CRPC, DDX5, HSP27, TFIIH
23  2022 Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models. CNS, iPSC
24  2022 Development and application of ribonucleic acid therapy strategies against COVID-19. COVID-19, PTGS, RNAi, SARS-CoV-2
25  2022 Development of Therapeutic RNA Manipulation for Muscular Dystrophy. DMD
26  2022 Divergence of Chemerin Reduction by an ATS9R Nanoparticle Targeting Adipose Tissue In Vitro vs. In Vivo in the Rat. ATS, Epi, NPs, RP
27  2022 Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells. CRP, IL-6, PBMC, TLR
28  2022 Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. CF, CFTR, mRNA
29  2022 Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. NOS2, STAT6, TAMs
30  2022 Gene Regulation Using Nanodiscs Modified with HIF-1-α Antisense Oligonucleotides. ND
31  2022 Genetic interaction between Scn8a and potassium channel genes Kcna1 and Kcnq2. ---
32  2022 Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. ALS, FUS, SMA, SOD1
33  2022 Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease. HD, HTT, SNPs
34  2022 Host-Directed Targeting of LincRNA-MIR99AHG Suppresses Intracellular Growth of Mycobacterium tuberculosis. LNA, lncRNAs, Mtb, TB
35  2022 Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides. ---
36  2022 Inotersen and severe thrombocytopenia: 2 case reports and review. 2'-MOE, hATTR
37  2022 Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. apoC-III, CVD
38  2022 Intracellular Absolute Quantification of Oligonucleotide Therapeutics by NanoSIMS. ---
39  2022 Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson's disease. AAV, DA, PD
40  2022 LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway. ELISA, HOTAIR, lncRNA, NSCLC, RT-qPCR
41  2022 Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2. Bcl-2
42  2022 Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis. MAT
43  2022 N-gene-complementary antisense-oligonucleotide directed molecular aggregation of dual-colour carbon dots, leading to efficient fluorometric sensing of SARS-COV-2 RNA. AIEE, CDs
44  2022 Non-invasive Imaging of Antisense Oligonucleotides in the Brain via In Vivo Click Chemistry. CNS, PET
45  2022 Non-viral vectors for RNA delivery. LNPs, miRNA, mRNA, siRNA
46  2022 Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. ALS, CSF, DPR, FTD
47  2022 Polyamide Microsized Particulate Polyplex Carriers for the 2'-OMethylRNA EFG1 Antisense Oligonucleotide. MPs
48  2022 Polycation Architecture Affects Complexation and Delivery of Short Antisense Oligonucleotides: Micelleplexes Outperform Polyplexes. DB
49  2022 Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice. ---
50  2022 Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension. ---
51  2022 Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides. CNS, EAE, HDO, MS, MSR1
52  2022 RNA interference as a novel treatment strategy for chronic hepatitis B infection. CHB, HBsAg, HBV, NAs, RNAi, siRNA
53  2022 RNA-targeting and gene editing therapies for transthyretin amyloidosis. ATTR, siRNA, TTR
54  2022 RNA-targeting strategies as a platform for ocular gene therapy. CRISPR, LCA, RNAi
55  2022 Safety and efficacy of therapies for chylomicronemia. ANGPTL3, apo, FCS, siRNA
56  2022 Single-gene diagnostic assay for rapid subclassification of basal like breast cancer with mRNA targeted antisense oligonucleotide capped molecular probe. BLBCs, FISH, FOXC1, TNBCs
57  2022 Suppression of Aquaporin-4 By Antisense Oligonucleotides Reduces Brain Edema In Experimental Traumatic Brain Injury. AQP4, DMEM, i.c.v, MR
58  2022 SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease. HD, HTT, iPSC-NPCs
59  2022 Synaptotagmin 11 scaffolds MKK7-JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. ANGPTL2, EMT, GC, JAM3, JNK, shSYT11, THBS4
60  2022 Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve. DRG, HDO
61  2022 Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia. ApoA1, ASCVD, CVD, DKO, FH, HCHF, HDL-C, HTG, LPL, PLT, TC, TG
62  2022 Targeting circNCLN/miR-291a-3p/TSLP signaling axis alleviates lipopolysaccharide-induced acute lung injury. ALI, LPS, TSLP
63  2022 Targeting of noncoding RNAs encoded by a novel MYC enhancers inhibits the proliferation of human hepatic carcinoma cells in vitro. eRNA, HCC
64  2022 The promising novel therapies for familial hypercholesterolemia. FH, siRNA
65  2022 Transdermal delivery of poly-hyaluronic acid-based spherical nucleic acids for chemogene therapy. DOX, HS, PHA, SNA, TIMP-1
66  2022 Treatment potential in APOL1-associated nephropathy. APOL1
67  2022 Use of antisense oligonucleotides to target Notch3 in skeletal cells. LMS
68  2022 Validation and application of hybridization liquid chromatography-tandem mass spectrometry methods for quantitative bioanalysis of antisense oligonucleotides. CSF, GLP
69  2022 [Treating hereditary neuropathies : a dream come true?] CMT, hTTR, siRNA
70  2021 A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. ADCs, FDA, Ro5
71  2021 All our knowledge begins with the antisenses. ---
72  2021 Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions. ---
73  2021 An Insight on RNA Based Therapeutics and Vaccines: Challenges and Opportunities. gRNA, siRNA
74  2021 An oral antisense oligonucleotide for PCSK9 inhibition. LDL, PCSK9
75  2021 Antisense locked nucleic acid gapmers to control Candida albicans filamentation. LNA
76  2021 Antisense Oligonucleotide In Vitro Protein Binding Determination in Plasma, Brain, and Cerebral Spinal Fluid Using Hybridization LC-MS/MS. CSF, PK/PD
77  2021 Antisense oligonucleotide technology as a research tool in plant biology. ---
78  2021 Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome. MeCP2
79  2021 Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model. DEE
80  2021 Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. 2'MOE, CF
81  2021 Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment. ER, PR, TNBC
82  2021 Antisense Oligonucleotide-Based Therapy of Viral Infections. ---
83  2021 Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy. DMD
84  2021 Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice. ANGPTL3, RCT
85  2021 Antisense oligonucleotide-mediated knockdown of Mpzl3 attenuates the negative metabolic effects of diet-induced obesity in mice. HED, KO, Mpzl3
86  2021 Antisense Oligonucleotide-Mediated Reduction of HDAC6 Does Not Reduce Tau Pathology in P301S Tau Transgenic Mice. AD, HDAC6
87  2021 Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. ASOs, NA, PS, TLR
88  2021 Antisense oligonucleotides targeting alternative splicing of Nrcam exon 10 suppress neurite outgrowth of ganglion sensory neurons in vitro. DRG, NrCAM
89  2021 Antisense technology: an overview and prospectus. ---
90  2021 Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. AxD
91  2021 ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. cEt, HCC
92  2021 Challenges and Opportunities for Nucleic Acid Therapeutics. mRNA
93  2021 Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. DDS, LNP
94  2021 Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. MALAT1
95  2021 Dietary and Pharmacologic Manipulations of Host Lipids and Their Interaction With the Gut Microbiome in Non-human Primates. IDOL, LXR, NPC1L1
96  2021 DNA Nanodevice as a Co-delivery Vehicle of Antisense Oligonucleotide and Silver Ions for Selective Inhibition of Bacteria Growth. ---
97  2021 DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo. HDO
98  2021 Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy. AAV, DS
99  2021 Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice. FL-SMN, SMA, SMN, SMN1
100  2021 Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases. DMD